desipramine has been researched along with moclobemide in 21 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 7 (33.33) | 18.2507 |
| 2000's | 8 (38.10) | 29.6817 |
| 2010's | 6 (28.57) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Topliss, JG; Yoshida, F | 1 |
| Lombardo, F; Obach, RS; Waters, NJ | 1 |
| Bleich, S; Kornhuber, J; Rupprecht, R; Terfloth, L; Wiltfang, J | 1 |
| Chupka, J; El-Kattan, A; Feng, B; Miller, HR; Obach, RS; Troutman, MD; Varma, MV | 1 |
| Chang, G; El-Kattan, A; Miller, HR; Obach, RS; Rotter, C; Steyn, SJ; Troutman, MD; Varma, MV | 1 |
| Afshari, CA; Eschenberg, M; Hamadeh, HK; Lee, PH; Lightfoot-Dunn, R; Morgan, RE; Qualls, CW; Ramachandran, B; Trauner, M; van Staden, CJ | 1 |
| Sen, S; Sinha, N | 1 |
| Artursson, P; Haglund, U; Karlgren, M; Kimoto, E; Lai, Y; Norinder, U; Vildhede, A; Wisniewski, JR | 1 |
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
| Coquoz, D; Dayer, P; Porchet, HC | 2 |
| Gabelic, I; Moll, E | 1 |
| Blier, P; De Montigny, C; Mongeau, R | 1 |
| Amrein, R; Cesura, AM; Hartmann, D; Schmid-Burgk, W | 1 |
| Fawcett, JP; Menkes, DB; Patel, PP | 1 |
| Finberg, JP; Lavian, G; Youdim, MB | 1 |
| Huang, WC; Li, YF; Liu, YQ; Luo, ZP | 1 |
| Chojnacka-Wójcik, E; Kłodzińska, A; Stachowicz, K; Tatarczyńska, E | 1 |
| Cao, JB; Guan, TT; Li, YF; Liu, YQ; Luo, ZP; Wang, HL; Zhang, YZ | 1 |
| Chojnacka-Wójcik, E; Nikiforuk, A; Tatarczyńska, E; Wesołowska, A | 1 |
| Fisar, Z; Hroudová, J; Raboch, J | 1 |
3 trial(s) available for desipramine and moclobemide
| Article | Year |
|---|---|
[Central analgesic effects of antidepressant drugs with various mechanisms of action: desipramine, fluvoxamine and moclobemide].
Topics: Analgesics; Antidepressive Agents; Benzamides; Desipramine; Double-Blind Method; Electric Stimulation; Fluvoxamine; Humans; Moclobemide; Monoamine Oxidase Inhibitors; Pain; Sural Nerve | 1991 |
Moclobemide (Ro 11-1163) versus desipramine in the treatment of endogenous depression.
Topics: Antidepressive Agents; Benzamides; Blood Pressure; Depressive Disorder; Desipramine; Dose-Response Relationship, Drug; Humans; Moclobemide; Monoamine Oxidase Inhibitors; Psychiatric Status Rating Scales | 1990 |
Central analgesic effects of desipramine, fluvoxamine, and moclobemide after single oral dosing: a study in healthy volunteers.
Topics: Administration, Oral; Adult; Analgesics; Analysis of Variance; Benzamides; Desipramine; Double-Blind Method; Fluvoxamine; Humans; Male; Moclobemide; Reference Values | 1993 |
18 other study(ies) available for desipramine and moclobemide
| Article | Year |
|---|---|
QSAR model for drug human oral bioavailability.
Topics: Administration, Oral; Biological Availability; Humans; Models, Biological; Models, Molecular; Pharmaceutical Preparations; Pharmacokinetics; Structure-Activity Relationship | 2000 |
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Molecular properties of psychopharmacological drugs determining non-competitive inhibition of 5-HT3A receptors.
Topics: Binding Sites; Computer Simulation; Databases, Factual; Models, Chemical; Models, Molecular; Molecular Structure; Molecular Weight; Psychotropic Drugs; Serotonin 5-HT3 Receptor Antagonists; Structure-Activity Relationship | 2009 |
Physicochemical determinants of human renal clearance.
Topics: Humans; Hydrogen Bonding; Hydrogen-Ion Concentration; Hydrophobic and Hydrophilic Interactions; Kidney; Metabolic Clearance Rate; Molecular Weight | 2009 |
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Topics: Administration, Oral; Biological Availability; Humans; Intestinal Absorption; Pharmaceutical Preparations | 2010 |
Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Assay; Biological Transport; Cell Line; Cell Membrane; Chemical and Drug Induced Liver Injury; Cytoplasmic Vesicles; Drug Evaluation, Preclinical; Humans; Liver; Rats; Reproducibility of Results; Spodoptera; Transfection; Xenobiotics | 2010 |
Predicting hERG activities of compounds from their 3D structures: development and evaluation of a global descriptors based QSAR model.
Topics: Computer Simulation; Ether-A-Go-Go Potassium Channels; Humans; Molecular Structure; Organic Chemicals; Quantitative Structure-Activity Relationship | 2011 |
Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.
Topics: Atorvastatin; Biological Transport; Drug Interactions; Estradiol; Estrone; HEK293 Cells; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; In Vitro Techniques; Least-Squares Analysis; Liver; Liver-Specific Organic Anion Transporter 1; Models, Molecular; Multivariate Analysis; Organic Anion Transporters; Organic Anion Transporters, Sodium-Independent; Protein Isoforms; Pyrroles; Solute Carrier Organic Anion Transporter Family Member 1B3; Structure-Activity Relationship; Transfection | 2012 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
Effect of long-term administration of antidepressant drugs on the 5-HT3 receptors that enhance the electrically evoked release of [3H]noradrenaline in the rat hippocampus.
Topics: Animals; Antidepressive Agents; Benzamides; Desipramine; Electric Stimulation; Fluoxetine; Hippocampus; In Vitro Techniques; Male; Maprotiline; Moclobemide; Norepinephrine; Rats; Rats, Sprague-Dawley; Receptors, Serotonin; Serotonin; Trimipramine | 1994 |
Relevance of reversible inhibitors of monoamine oxidase type A and of reuptake inhibition for noradrenaline turnover.
Topics: Animals; Benzamides; Brain; Cytoplasm; Depressive Disorder; Desipramine; Humans; Kinetics; Moclobemide; Monoamine Oxidase Inhibitors; Neurons; Norepinephrine; Synaptic Vesicles | 1995 |
Antidepressant treatment and chemical sympathectomy fail to modulate alpha 1-adrenoceptor sensitivity in mouse eye.
Topics: Administration, Topical; Amitriptyline; Animals; Antidepressive Agents; Benzamides; Desipramine; Down-Regulation; Fluoxetine; Injections, Intraperitoneal; Male; Methoxamine; Mice; Moclobemide; Oxidopamine; Phentolamine; Phenylephrine; Prazosin; Pupil; Receptors, Adrenergic, alpha-1; Sympathectomy, Chemical; Time Factors | 1993 |
The advent of a new generation of monoamine oxidase inhibitor antidepressants: pharmacologic studies with moclobemide and brofaromine.
Topics: Animals; Antidepressive Agents; Benzamides; Blood Pressure; Clorgyline; Desipramine; Heart Rate; Kidney; Moclobemide; Monoamine Oxidase Inhibitors; Piperidines; Rats; Rats, Sprague-Dawley; Sympathetic Nervous System | 1993 |
Cytoprotective effect is one of common action pathways for antidepressants.
Topics: Animals; Anticonvulsants; Calcium; Cell Survival; Corticosterone; Desipramine; Fluoxetine; Moclobemide; Nerve Growth Factor; Neuroprotective Agents; PC12 Cells; Rats; RNA, Messenger | 2003 |
Effect of combined administration of 5-HT1A or 5-HT1B/1D receptor antagonists and antidepressants in the forced swimming test.
Topics: Adrenergic Uptake Inhibitors; Animals; Antidepressive Agents; Antidepressive Agents, Tricyclic; Citalopram; Depression; Desipramine; Imipramine; Male; Moclobemide; Monoamine Oxidase Inhibitors; Oxadiazoles; Piperazines; Pyridines; Rats; Rats, Wistar; Receptor, Serotonin, 5-HT1A; Receptor, Serotonin, 5-HT1B; Selective Serotonin Reuptake Inhibitors; Serotonin Antagonists; Swimming | 2004 |
Inhibition of N-methyl-D-aspartate receptor function appears to be one of the common actions for antidepressants.
Topics: Animals; Antidepressive Agents; Antidepressive Agents, Second-Generation; Antidepressive Agents, Tricyclic; Calcium; Calcium Signaling; Cell Survival; Desipramine; Excitatory Amino Acid Antagonists; Fluoxetine; Hippocampus; L-Lactate Dehydrogenase; Moclobemide; Monoamine Oxidase Inhibitors; N-Methylaspartate; Neurons; Nitric Oxide Synthase Type I; PC12 Cells; Rats; Receptors, N-Methyl-D-Aspartate; Signal Transduction; Tetrazolium Salts; Thiazoles | 2006 |
Enhancement of the anti-immobility action of antidepressants by a selective 5-HT7 receptor antagonist in the forced swimming test in mice.
Topics: Adrenergic Uptake Inhibitors; Animals; Antidepressive Agents; Citalopram; Desipramine; Drug Interactions; Imipramine; Male; Mice; Moclobemide; Monoamine Oxidase Inhibitors; Motor Activity; Phenols; Receptors, Serotonin; Selective Serotonin Reuptake Inhibitors; Serotonin Antagonists; Sulfonamides; Swimming | 2007 |
Inhibition of monoamine oxidase activity by antidepressants and mood stabilizers.
Topics: Affect; Amitriptyline; Animals; Antidepressive Agents; Antimanic Agents; Benzodiazepines; Cerebral Cortex; Citalopram; Clorgyline; Cocaine; Cyclohexanols; Desipramine; Fluoxetine; Imipramine; In Vitro Techniques; Iproniazid; Lithium; Mianserin; Mirtazapine; Mitochondria; Moclobemide; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Morpholines; Olanzapine; Pargyline; Reboxetine; Swine; Thiazepines; Valproic Acid; Venlafaxine Hydrochloride | 2010 |